case_images: PMC5742436_01
case_images: BCR-ABL1 transcript levels throughout clinical course.
case_images: CRIHEM2017-3548936.001.jpg
case_images: PMC5742436_01_CRIHEM2017-3548936.001.jpg
case_images: fig1
case_images: BCR-ABL1/ABL1 0.09% on the International Scale (IS) at 20 months (Figure 1). BCR-ABL1 transcripts became undetectable (<0.001% IS) at 40 months with optimal adherence and a good quality of life. Rising transcript levels resulted in loss of MMR at 105 months, peaking at a BCR-ABL1/ABL1 IS of 3.43%, almost nine years after starting imatinib (Figure 1). The BCR-ABL1 transcript level continues to decline (Figure 1) with continued frequent monitoring advocated.